Reviva Pharmaceuticals enters into ATM sales agreement for up to $50M common stock offering

REVIVA PHARMACEUTICALS HOLDINGS, INC.

On May 30, 2025, Reviva entered an ATM agreement with B. Riley Securities and Alliance Global Partners to sell up to $50M of common stock.
Sales will be made through Nasdaq as an 'at the market offering' under Rule 415; agents receive 3% commission.
Shares issued under effective shelf registration statement (Form S-3 filed Feb 2024).
No obligation for agents to sell any specific amount; they use commercially reasonable efforts based on company instructions.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.